Classifications

• • C—CHEMISTRY; METALLURGY
  • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
  • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
  • C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
  • C08G73/02—Polyamines
  • C08G73/026—Wholly aromatic polyamines
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
  • A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
  • A61L24/001—Use of materials characterised by their function or physical properties
  • A61L24/0015—Medicaments; Biocides
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
  • A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
  • A61L24/001—Use of materials characterised by their function or physical properties
  • A61L24/0042—Materials resorbable by the body
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
  • A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
  • A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
  • A61L24/046—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
  • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
  • A61L27/28—Materials for coating prostheses
  • A61L27/34—Macromolecular materials
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
  • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
  • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
  • A61L27/54—Biologically active materials, e.g. therapeutic substances
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
  • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
  • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
  • A61L27/58—Materials at least partially resorbable by the body
• • C—CHEMISTRY; METALLURGY
  • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
  • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
  • C08G12/00—Condensation polymers of aldehydes or ketones with only compounds containing hydrogen attached to nitrogen
• • C—CHEMISTRY; METALLURGY
  • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
  • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
  • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
  • C08G65/34—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from hydroxy compounds or their metallic derivatives
  • C08G65/38—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from hydroxy compounds or their metallic derivatives derived from phenols
  • C08G65/40—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from hydroxy compounds or their metallic derivatives derived from phenols from phenols (I) and other compounds (II), e.g. OH-Ar-OH + X-Ar-X, where X is halogen atom, i.e. leaving group
  • C08G65/4012—Other compound (II) containing a ketone group, e.g. X-Ar-C(=O)-Ar-X for polyetherketones
  • C08G65/4031—(I) or (II) containing nitrogen
• • C—CHEMISTRY; METALLURGY
  • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
  • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
  • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
  • C08G65/34—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from hydroxy compounds or their metallic derivatives
  • C08G65/38—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from hydroxy compounds or their metallic derivatives derived from phenols
  • C08G65/40—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from hydroxy compounds or their metallic derivatives derived from phenols from phenols (I) and other compounds (II), e.g. OH-Ar-OH + X-Ar-X, where X is halogen atom, i.e. leaving group
  • C08G65/4075—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from hydroxy compounds or their metallic derivatives derived from phenols from phenols (I) and other compounds (II), e.g. OH-Ar-OH + X-Ar-X, where X is halogen atom, i.e. leaving group from self-polymerisable monomers, e.g. OH-Ar-X
• • C—CHEMISTRY; METALLURGY
  • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
  • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
  • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
  • C08G65/34—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from hydroxy compounds or their metallic derivatives
  • C08G65/38—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from hydroxy compounds or their metallic derivatives derived from phenols
  • C08G65/44—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from hydroxy compounds or their metallic derivatives derived from phenols by oxidation of phenols
• • C—CHEMISTRY; METALLURGY
  • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
  • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
  • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
  • C08G65/34—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from hydroxy compounds or their metallic derivatives
  • C08G65/48—Polymers modified by chemical after-treatment
• • C—CHEMISTRY; METALLURGY
  • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
  • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
  • C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
  • C08G73/02—Polyamines
• • C—CHEMISTRY; METALLURGY
  • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
  • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
  • C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
  • C08G73/02—Polyamines
  • C08G73/0206—Polyalkylene(poly)amines
• • C—CHEMISTRY; METALLURGY
  • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
  • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
  • C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
  • C08G73/02—Polyamines
  • C08G73/0206—Polyalkylene(poly)amines
  • C08G73/0213—Preparatory process
• • C—CHEMISTRY; METALLURGY
  • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
  • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
  • C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
  • C08G73/02—Polyamines
  • C08G73/024—Polyamines containing oxygen in the form of ether bonds in the main chain
• • C—CHEMISTRY; METALLURGY
  • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
  • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
  • C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
  • C08G73/02—Polyamines
  • C08G73/0246—Polyamines containing other atoms than carbon, hydrogen, nitrogen or oxygen in the main chain
  • C08G73/0253—Polyamines containing sulfur in the main chain
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
  • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
  • A61F2/0077—Special surfaces of prostheses, e.g. for improving ingrowth
  • A61F2002/0086—Special surfaces of prostheses, e.g. for improving ingrowth for preferentially controlling or promoting the growth of specific types of cells or tissues
• • C—CHEMISTRY; METALLURGY
  • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
  • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
  • C08G2150/00—Compositions for coatings
• • C—CHEMISTRY; METALLURGY
  • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
  • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
  • C08G2170/00—Compositions for adhesives
  • C08G2170/80—Compositions for aqueous adhesives
• • C—CHEMISTRY; METALLURGY
  • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
  • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
  • C08G2230/00—Compositions for preparing biodegradable polymers

Definitions

• the present invention relates to the field of catecholamine-based membranes.
• the present invention provides a self-standing catecholamine membrane, a process for its preparation and uses thereof.
• Catechol derivatives are widely distributed among natural, animal and plant systems, all of them characterized by sharing an aromatic core of formula (I):
• DOPA 3,4-dihydroxyphenylalanine
• DOPA 3,4-dihydroxyphenylalanine
• a well-known nucleophile is the amine that may react with o-quinones to form adducts either by Michael addition or Schiff base reaction.
• catechol derivatives and amines are of vital importance in natural biological processes, such as the cross-linking of adhesive proteins by marine organisms, the formation of the cytoskeleton by insects and the biosynthesis of melanin.
• This catechol-amine chemistry occurring in natural organisms has attracted much attention in material science due to the increasing interest in finding new materials.
• Many publications have reported the preparation of catecholamine-based coatings. For example, lacomino M. and colleagues (lacomino M.
• self-supporting polymer films can be prepared from crosslinked, self-assembled monolayer films by surface-initiated polymerization reactions, which have very thin properties, as well as good chemical stability and sensitivity.
• this method requires the use of electron beams for crosslinking, and severe conditions may affect the broad application of the method.
• a method including gas/liquid interface assembly or asymmetric modification was also studied, forming a polydopamine film at an air-water interface.
• the film material was easy to generate cracks during the preparation process, and the stability of the film was found to be poor.
• Other research groups have been studying the synthesis using polyethyleneimine (PEI) as a supporting material.
• PEI polyethyleneimine
• Ponzio F. and colleagues disclosed the use of PEI to confer hardiness to a membrane-based on dopamine.
• the reaction conditions require a basic pH and under biological environment, the presence of PEI provides toxic by-products, limiting the use of these membranes.
• the present inventors have developed a new process for obtaining free-standing catecholamine-based membranes with very advantageous mechanical features, but also with a profile of degradability, adhesion and cell proliferation that make them especially useful in therapeutic and diagnostic applications.
• the process of the invention is based on the particular selection of an amine, either an aliphatic amine which is a hydrocarbon chain having a terminal amine at each end of the chain or an aromatic amine, as a crosslinker agent, as well as on the strict reaction conditions of pH and agitation.
• the pH reaction conditions are so mild that they allow the in situ functionalization with biological molecules, something advantageous when compared with processes of the prior art, which work under basic conditions.
• the invention provides a process for preparing a catecholamine-based membrane, the process comprising the steps of: a) crosslinking a catechol derivative with an amine selected from the group consisting of: a.1) a known aliphatic amine of formula (II)
• B represents a (Ci-C2o)alkylene; (Ci-C2o)alkylene substituted with one or more substituents selected from the group consisting of: -OH, halogen, -NO2, cyano, -0-(Ci-Cio)alkyi, -C(0)0R2, and -NR 3 R’ 3 ; (C2-C2o)alkenylene; (C2-C2o)alkenylene substituted with one or more substituents selected from the group consisting of: -OH, halogen, -NO2, cyano, -0-(Ci-Cio)alkyi, -C(0)0R4, and -NRsR's; (C2-C2o)alkynylene; (C2-C2o)alkynylene substituted with one or more substituents selected from the group consisting of: -OH, halogen, -NO2, cyano, -0-(Ci-Cio)alkyi, -
• A is bound to the first atom member forming part of the B biradical hydrocarbon backbone; A is bound to the last atom member forming part of the B biradical hydrocarbon backbone; wherein the "first” and “last” atom members are identified reading the B biradical hydrocarbon backbone from left to right or vice versa;
• Ri, R'i, R 3I R’ 3I R 5 , R' 5 , R7, RV, Rg , R’g, R 11 , and R'n are the same or different and are selected from the group consisting of: -H; (Ci-Cio)alkyl; (Ci-Cio)haloalkyl; (C2-Cio)alkenyl; (C2-Cio)al kynyl; (Ci-Cio)al kyl substituted with one or more substituents selected from the group consisting of -OH, -NO2, cyano, -0-(Ci-Cio)alkyi, -C(0)0Ri2, and -NRI 3 R’I 3 ;
• R2, R 4 , R 6 , Re, R10 and R12 are independently selected from the group consisting of - H; (Cr Cio)alkyl; (Ci-Cio)haloalkyl; (C2-Cio)alkenyl; (C2-Cio)al kynyl; (Ci-Cio)al kyl substituted with one or more substituents selected from the group consisting of -OH, -NO2, cyano, -0-(Cr Cio)alkyl, -C(0)0Ruand -NRisR'is;
• Ri3, R’ 13 , Ri4, Ri5 and R' isare the same or different and are selected from the group consisting of: -H; (Ci-Cio)alkyl; (Ci-Cio)haloalkyl; (C2-Cio)alkenyl; and (C2-Cio)alkynyl;
• a "known 3- to 20-membered heteroalkylene” means a known saturated chain consisting of from 3 to 20 members selected from the group consisting of C(R X )2, CR X , -N-, -NR' X -, -S-, and -0-, provided that: (a) at least one of the members is -N-, -NR X -, -S-, or -0-; and (b) the first and the last members forming the backbone of the heteroalkylene are carbon atoms;
• a "known 3 to 20-membered heteroalkenylene” means a known unsaturated chain consist
• R x is independently selected from the group consisting of -H; -OH; (Ci-Cio)alkyl; (C2-Cio)alkenyl; (C2-Cio)alkynyl; (Ci-Cio)haloalkyl; 0-(Ci-Cio)alkyi; -0-(C2-Cio)alkenyl; -0-(C2-Cio)al kynyl; nitro, -NR xi R x 2; (Ci-Cio)alkyl substituted with one or more substituents selected from the group consisting of -OH, -NO2, cyano, -0-(Ci-Cio)alkyi, -C(0)0Ri 6 , and -NRizR ; and halogen; and
• Rxi, R X 2, R16 , Ri7, R'i7, and R' x are independently selected from the group consisting of -H, (Ci-Cio)alkyl, (C2-Cio)alkenyl, (C2-Cio)al kynyl, and (Ci-Cio)haloalkyl; and a.2) an aromatic amine of formula (llbis):
• L is selected from the group consisting of: (CrCio)alkyl substituted with one or more substituents selected from the group consisting of -OH, -NO2, cyano, -0-(Ci-Cio)alkyi, -C(0)0R 28 , and -NR28R’2s, provided that at least one of the substituents is -NR2sR'28; (Ci-Cio)haloalkyl substituted with one or more substituents selected from the group consisting of -OH, -NO2, cyano, -0-(Cr Cio)alkyl, -C(0)0R 28 , and -NR2sR'28, provided that at least one of the substituents is -NR28R'2s; (C2- Cio)alkenyl substituted with one or more substituents selected from the group consisting of -OH, -NO2, cyano, -0-(Ci-Cio)alkyi, -C(0)0R
• Rz, and R' z are independently selected from the group consisting of: H, (Ci-Cio)alkyl; (Ci-Cio)haloalkyl;
• R28, R'28, R29, R30, R'30, R31, R’31, R32, R33, R'33, R34, R35, and R’35 are independently selected from the group consisting of: -H; (Ci-Cio)alkyl; (Ci-Cio)haloalkyl; (C2-C 10) al keny I ; and (C2-Cio)alkynyl; to create a catecholamine membrane in the air/liquid interface in the absence of any support, the crosslinking reaction being performed in a liquid medium, wherein both the catechol and the amine are soluble at a pH comprised from 6.5 to 10, particularly from 6.5 to 8 and under agitation, particularly appropriate agitation; and b) isolating the membrane resulting from step (a) from the air/liquid interface.
• the formation of the membranes takes place in the liquid-air interface, avoiding the use of substrates (e.g., glass, metals) or of the polymers which in situ provides the support (e.g., polyethyleneimine, PEI).
• substrates e.g., glass, metals
• PEI polyethyleneimine
• the process of the invention allows for extremely control of the resulting features.
• One of the characteristics that can be controlled is the final thickness of the membranes. This control can be easily achieved through the concentration and reaction time. The increase of the concentration of the starting reagents, together with higher reaction times, results in the formation of thicker membranes. With this control, it is possible to fabricate membranes with thickness ranging from 50 nm to 3 pm when measured by scanning electron microscopy (SEM) and atomic force microscopy (AFM), as provided below. Worth to mention that thicker membranes are easily handled compare with thinner membranes. Nevertheless, in all the cases was possible to isolate the floating membranes for their characterization and use (via functionalization).
• the membrane obtainable by the process of the invention is a free-standing membrane (also so-called self-supported or self-standing membrane), which means that it does not require a support for the polymerization.
• the membrane resulting from the process of the invention shows some advantageous properties.
• the membranes resulting from the process of the invention were robust, easy to handle and manipulate, highly flexible and adaptable to any kind of surface without breaking. In fact, they could be cut easily in different morphologies (e.g., squares, rectangles) using a sharp tool (e.g., scalpel or scissors) or produced in prefabricated molds with the desired morphology. Contrary to the membrane obtained from aliphatic monoamines having a terminal amine only at one end of the hydrocarbon chain which were so fragile in the absence of support that no formal membrane could be achieved, in spite of the efforts made by the inventors.
• the free-standing membrane of the invention shows a Janus character. They exhibited not only a different roughness depending on the side but also asymmetric chemistry. Particularly, the present inventors found that the side in contact with liquid medium (in the examples, water) presented higher roughness because of the creation of a nanopatterning based on catecholamine nanoparticles (produced during the process of the invention), while the air-contact side was smoother. Surprisingly, the inventors found that once the membranes of the invention were formed and washed using ultrapure water, the nanopatterning of the liquid-side contact of the membranes remained invariable, i.e., the nanoparticles remained embedded in the surface.
• liquid medium in the examples, water
• Such morphological asymmetry property endows the membranes of the invention with added value as the liquid-contact (in the examples water-contact) side promotes a better cell adhesion compared with smoother surfaces observed in comparative synthesized membranes with PEI or using substrates, where the adhesion of cells was very low and its proliferation resulted in low density.
• the membrane showed similar features on both sides with a roughness around 3.5 nm on both sides due to the substrate, which avoids the formation of nanoparticles that subsequently cannot be embedded on the surface, forming the nanopatterning.
• the membrane of the invention is safe, being suitable to be used in contact with animal or human beings. As shown below, even degrading, the cells are able to adhere and grow on the membranes of the invention, contrary to the case wherein the membrane includes PEI (see examples below).
• the membrane of the invention shows improved features with respect to the catecholamine-based membranes reported in the prior art.
• the present invention provides a self-standing catecholamine-based membrane obtainable by the process of the first aspect of the invention.
• the membranes of the invention are particularly efficient in supporting the adhesion and differentiation of cells, which is indicative of its innate regenerative ability. This is greatly due to the roughness and Janus character shown by the membranes of the invention, which, in addition, confers to the membrane of the invention the ability to be easily functionalized with a molecule of interest, either with a therapeutic profile or visualization means.
• the adhesion of cells is favoured in rough surfaces, thus enhancing their proliferation and growth.
• This property is of special interest for applying the membranes in tissue regeneration as they can be used as a platform for the growth of new tissue in damaged areas.
• the present invention provides the catecholamine-based membrane as defined in the second aspect of the invention further comprising one or more therapeutic molecules for use in therapy, or alternatively, the catecholamine-based membrane as defined in the second aspect of the invention further comprising one or more detection labels for use in diagnosis.
• a fourth aspect of the invention relates to the catecholamine-based membrane as defined in the second aspect of the invention, which further comprises one or more molecules of interest selected from the group consisting cells, growth factors and combinations thereof for use in regenerating tissues.
• the present invention provides the use of the catecholamine-based membrane as defined in the second aspect of the invention as an adhesive (for example in the form of a patch).
• the present invention provides the use of the catecholamine-based membrane as defined in the second aspect of the invention as a vehicle of a molecule of interest.
• the present invention provides an article, such as a medical device and/or electronic parts (e.g., electrodes or sensors), which is partially or totally coated with the self-standing membrane of the second aspect of the invention.
• a medical device and/or electronic parts e.g., electrodes or sensors
• FIG. 1 corresponds to SEM images of different membranes.
• the flexibility of the membranes is corroborated by the lack of cracks or fissures, a) rolled membrane (1-7) showing the high flexibility, b) rolled membrane (3-7) with high flexibility, c) rolled membrane (2-7) showing the air-contact side; d) water-contact side of membrane (2-7), e) water-contact side of membrane (3-7), f) flexibility showed by the membrane (5-7) and with the air-contact side exposed, g) air-contact side of the membrane (1-11) and h) water- contact side of membrane (1-11).
• any ranges given include both the lower and the upper end-points of the range.
• the present invention provides a process for preparing a catecholamine-based membrane.
• catecholamine-based membrane and “catecholamine-based film” have the same meaning and can be interchangeably used and refers to a material made with a catechol derivative crosslinked with an amine compound.
• the catechol derivative is any compound including a moiety of formula (I), whereas the amine is an aliphatic amine of formula (II) or an aromatic amine of formula (llbis).
• the crosslinking can be confirmed by any suitable routinary technique such as infrared (FT-IR) or UV-visible spectroscopy.
• the inventors confirmed the successful cross-linking of the amine of formula (II) or (llbis) with the catechol derivative by detecting covalent bonding formation between the catechol derivative and the amine-based ligand.
• This covalent interaction will depend on the functional groups of the catechol reacting with terminal amino groups.
• the polymerization of catechol-derivatives with amino-based molecules can be corroborated using FT-IR spectroscopy. For example, the decrease of intensity bands associated with hydroxyl groups, appearing in the range of 3600- 3000 cm ⁇ 1 , is a signal of copolymerization.
• the catechol derivative can be any including a moiety of formula (I). That is, the catechol derivative in the context of the invention is any compound comprising or consisting of a 6- membered aromatic ring, showing two vicinal hydroxyl groups (o-benzenediol).
• This catechol skeleton of formula (I) occurs in a variety of natural products such as drugs imitating them (such as MDMA), hormones/neurotransmitters, and catechin, which is found in tea. Many pyrocatechin derivatives have been suggested for therapeutic applications. Furthermore, there are many catechol derivatives commercially available from several companies (such as Sigma-Aldrich, Alfa Aesar and Fisher Scientific, among others).
• Illustrative non-limitative examples are pyrocatechol (CAS RN 120-80-9), pyrogallol (CAS RN 87-66-1), 4- methylcatechol (CAS RN 452-86-8), caffeic acid (CAS RN 331-39-5, 501-16-6, 71693-97-5), dopamine (CAS RN 51-61-6, 62-31-7), quercetin (CAS RN 117-39-5, 6151-25-3, 849061-97-8), hexahydroxy-triphenylene (CAS RN 4877-80-9), catechin (CAS RN 7295-85-4, 154-23-4, 18829-70-4, 225937-10-0), gallic acid (CAS RN 149-91-7, 5995-86-8), tannic acid (CAS RN 1401-55-4), and epigallocatechin gallate (CAS RN 989-51-5), among others.
• alkyl refers to a saturated linear or branched hydrocarbon chain containing the number of carbon atoms indicated in the claims and in the description.
• alkyl groups include, but are not limited to: methyl, ethyl, propyl, iso-propyl, butyl, isobutyl, tert-butyl, pentyl, hexyl, heptyl, octyl, nonanyl, decanyl, and the like.
• alkenyl refers to a saturated linear or branched hydrocarbon chain containing the number of carbon atoms indicated in the claims and in the description and containing one or more double bond(s).
• alkenyl groups include, but are not limited to: ethenyl, propenyl, butenyl, 1-methyl-2-buten-1-yl, and the like.
• alkynyl refers to a saturated linear or branched hydrocarbon chain containing the number of carbon atoms indicated in the claims and in the description, and one or more triple bond(s).
• alkyl groups include, but are not limited to: ethynyl, 1-propynyl, 2-butynyl, 1,3-butadinyl, 4-pentynyl, and 1-hexynyl, and the like.
• heteroalkylene and “known heteroalkenylene” refer to heteroalkylenes and heteroalkenylenes, which are known in the art and so intend to exclude those hetero systems that are not chemically possible.
• the term "known 3 to 20-membered heteroalkylene” refers to any known saturated chain comprising from 3 to 20 atoms selected from carbons and heteroatoms (i.e., atoms other than carbon atoms, such as N, O or S), provided that the first and last atoms forming the unsaturated chain are carbon atoms (to which A and A are bound).
• the member atoms are selected from the group consisting of -C(R X )2-, -CR X -, -N-, -NR' X -, -S-, and -0-, provided that at least one of the members is -N-, -NR X -, -S-, or -O-.
• the heteroalkylene chain can be linear or branched.
• R x is independently selected from the group consisting of -FI; -OH; (Ci-Cio)alkyl; (C2-C i o) al keny I ; (C2-C 10) al ky ny I ; (Ci-Cio)haloalkyl; 0-(Ci-Cio)alkyl; -O- (C2-C 10) al keny I ; -0-(C 2 -C 10) al ky ny I ; nitro, -NR X IR X 2; (Ci-Cio)alkyl substituted with one or more substituents selected from the group consisting of -OH, -NO2, cyano, -0-(Ci-Cio)alkyi, -C(0)0Ri 6 , and -NRizR ; and halogen.
• Rxi, R X 2, R16 , R17, R’17, and R' x are independently selected from the group consisting of -H, (Ci-Cio)alkyl, (C2-C 10) al keny I , (C2-C 10) al ky ny I , and (Ci-Cio)haloalkyl.
• the term "known 3 to 20-membered “heteroalkenylene”, refers to any known unsaturated chain, including one or more double bonds, and made from 3 to 20 member atoms selected from carbons and heteroatoms (i.e., atoms other than carbon atoms, such as N, 0 or S), provided that at least the first and last atoms forming the chain are carbon atoms (to which A and A are bound).
• the member atoms are selected from the group consisting of -C(R X )2-, -CR X -, -N-, -NR' X -, -S-, and -0-, provided that at least one of the members is -N-, -NR' X -, -S-, or -0-.
• the heteroalkylene chain can be linear or branched.
• R x is independently selected from the group consisting of -H; -OH; (Ci-Cio)alkyl; (C2-C 10) al keny I ; (C2-C 10) al ky ny I ; (Ci-Cio)haloalkyl; 0-(C 1 -C 10) al ky I ; -0-(C 2 -Cio)alkenyl; -0-(C 2 -Cio)al kynyl; nitro, -NR X IR X 2; (Cr Cio)alkyl substituted with one or more substituents selected from the group consisting of -OH, -NO2, cyano, -0-(Ci-Cio)alkyi, -C(0)0Ri6, and -NRizR ; and halogen.
• Rxi, R X 2, R16, R17, R’17, and R' x are independently selected from the group consisting of -H, (Ci-Cio)alkyl, (C2-C 10) al keny I , (C2-C 10) al ky ny I , and (Ci-Cio)haloalkyl.
• haloalkyl refers to a saturated linear or branched hydrocarbon chain containing the number of carbon atoms indicated in the claims and in the description, wherein at least one of the carbon atoms is substituted by at least one halogen.
• the number of carbon atoms of an alkyl, alkenyl, alkynyl, akylene, alkenylene, and alkynylene is represented by a "C” (symbol of the carbon atom) with a number in subindex format, which indicates the number of carbons.
• “Ci” means that the alkyl has a single carbon atom; and wherein reference is made to a range, in the form, for instance, of “(C1-C20)", it means that the hydrocarbon has from 1 to 20 carbon atoms.
• known ring system refers to a ring system, which is known in the art and so intends to exclude those ring systems that are not chemically possible.
• a ring system formed by "isolated” rings means that the ring system is formed by two, three or four rings and said rings are bound via a bond from the atom of one ring to the atom of the other ring.
• isolated also embraces the embodiment in which the ring system has only one ring.
• Illustrative non-limitative examples of known ring systems consisting of one ring are those derived from: cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclopropenyl, cyclobutenyl, cyclopentenyl, phenyl, biphenylyl, and cycloheptenyl.
• fused rings encompasses rings totally fused, partially fused or spiro fused.
• the ring system when the ring system is "totally fused” it means that the ring system is formed by two, three or four rings in which two or more atoms are common to two adjoining rings.
• Illustrative non-limitative examples are 1,2,3,4-tetrahydronaphthyl, 1 -naphthyl, 2-naphthyl, anthryl, or phenanthryl.
• the ring system when the ring system is "partially fused”, it means that the ring system is formed by three or four rings, being at least two of said rings totally fused (i.e. two or more atoms being common to the two adjoining rings) and the remaining ring(s) being bound via a bond from the atom of one ring to the atom of one of the fused rings.
• the ring system when the ring system is "spiro fused”, it means that the ring system comprises at least two rings sharing a common atom.
• the simplest spiro compounds are bicyclic (having just two rings), or have a bicyclic portion as part of the larger ring system, in either case with the two rings connected through the defining single common atom.
• Spiro compounds may be fully carbocyclic (all carbon) or heterocyclic (having one or more non-carbon atom forming part of the backbone of the rings).
• halo and halogen are used interchangeably and refer to a halogen group selected from the group consisting of chloro, fluoro, bromo and iodo.
• the catechol derivative is one of formula (III): wherein
• Ri8, Ri9, R'i8 and R’19 are the same or different and are selected from the group consisting of:
• (Ci-Cio)al kyl substituted with one or more substituents selected from the group consisting of: -OH, halogen, nitro, cyano, (Ci-Cio)alkyl, (Ci-Cio)haloalkyl, -NR2iR’2i, -C(0)0R22, and -0-(Ci-Cio)alkyi;
• R' y is selected from the group consisting of -H, (Ci-Cio)alkyl, (C2-Cio)alkenyl, (C2-Cio)alkynyl, and (Ci-Cio)haloalkyl;
• R20, R'20, R21, R’21, R23, R'23, R25, and R'25 are the same or different and are selected from the group consisting of: -H; (Ci-Cio)alkyl; (Ci-Cio)haloalkyl; (C2-C 1 0 ) al keny I ; (C2-C 1 0 ) al kynyl ; (Ci-Cio)alkyl substituted with one or more substituents selected from the group consisting of: -OH, halogen, nitro, cyano, (Ci-Cio)alkyl, (Ci-Cio)haloalkyl, -NR26R'26, -C(0)0R2z, and -0- (C 1 -C 10) al ky I ;
• R 22 and R 24 are independently selected from the group consisting of: H, (Ci-Cio)alkyl, (Ci-Cio)haloalkyl, (C2-C 1 0 ) al keny I ; and (C2-C 1 0 ) al kynyl ; and
• R 26 , R' 26 and R 27 are the same or different and are selected from the group consisting of: -H; (Cr Cio)alkyl; (Ci-Cio)haloalkyl; (C2-C 1 0 ) al keny I ; and (C2-Cio)alkynyl.
• the catechol derivative of formula (III) is one wherein Ris and R1 9 are the same or different and are selected from the group consisting of: -H; -OH; (Ci-Cio)alkyl; (Ci-Cio)alkyl substituted as defined above; and (C2-Cio)alkenyl substituted as defined above.
• the catechol derivative of formula (III) is one wherein one of Ris and Rig is a known ring system consisting of two rings, each one of the rings (a) consisting of 5-6 members selected from the group consisting of -C(R y ) 2 -, -CRy, -N-, -NR’y, -S-, and -0-, (b) being saturated, partially unsaturated or aromatic, and (c) being isolated, partially isolated or fused; wherein R y and R' y are as defined above.
• the catechol derivative of formula (III) is one wherein one of Ris and R1 9 is a known ring system consisting of two rings, each one of the rings (a) consisting of 6 members selected from the group consisting of -C(R y )3 ⁇ 4-, -CRy, -N-, -NR'y, -S-, and -0-, (b) being saturated, partially unsaturated or aromatic, and (c) being fused; wherein R y and R' y are as defined above.
• the catechol derivative of formula (III) is one wherein one of Ris and R1 9 is a known ring system consisting of two rings, each one of the rings (a) consisting of 6 members selected from the group consisting of -C(R y ) 2 -, -CRy, -N-, -NR'y, -S-, and -0-, provided that at least one of the rings includes a heteroatom (-N-, -NR' y , -S-, and -0-); (b) being saturated, partially unsaturated or aromatic, and (c) being fused; wherein R y and R' y are as defined above.
• the catechol derivative of formula (III) is one wherein one of Ris and R1 9 is a known ring system consisting of two rings, each one of the rings (a) consisting of 6 members selected from the group consisting of -C(R y ) 2 -, -CR y -, -N-, -NR' y -, -S-, and -0-, provided that at least one of the rings includes a -0- heteroatom; (b) being saturated, partially unsaturated or aromatic, and (c) being fused; wherein R y and R' y are as defined above.
• the catechol derivative of formula (III) is one wherein one of Ris and R 19 is a known ring system consisting of two rings, each one of the rings (a) consisting of 6 members selected from the group consisting of -C(R y ) 2, -, -CR y -, -0-, provided that at least one of the rings includes a -O-heteroatom; (b) being saturated, partially unsaturated or aromatic, and (c) being fused; wherein R y and R' y are as defined above.
• the catechol derivative of formula (III) is one wherein one of Ris and R 19 is a known ring system consisting of two rings, each one of the rings (a) consisting of 6 members selected from the group consisting of -C(R y ) 2 -, -CR y -, -0-, provided that only one of the rings includes a -O-heteroatom; (b) being saturated, partially unsaturated or aromatic, and (c) being fused; wherein R y and R' y are as defined above.
• the catechol of formula (III) is one wherein one of the Ris or Rig is -H and the other is as defined in any of the above embodiments.
• the catechol derivative of formula (III) is one wherein R'is and R’ig are -H and Ris and Rig are as defined in any of the above embodiments.
• the catechol derivative is selected from the group consisting of pyrocatechol, dopamine, pyrogallol, caffeic acid, 4- methylcatechol, and catechin.
• the amine is a known aliphatic amine of formula (II).
• the amine is a known aliphatic amine of formula (II) wherein A and A' are the same.
• the amine is a known aliphatic amine of formula (II) wherein A and A are the same or different and represent NHR'i.
• the amine is a known aliphatic amine of formula (II) wherein A and A are the same and represent NHR'i.
• the amine is a known aliphatic amine of formula (II) wherein at least one of A and A represents -NH 2 .
• the amine is a known aliphatic amine of formula (II) wherein A and A are the same and represent -NH 2 .
• the amine is a known aliphatic amine of formula (II) wherein B represents (Ci-C2o)alkylene; (Ci-C2o)alkylene substituted as defined above; or a known 3- to 20-membered heteroalkylene.
• the amine is a known aliphatic amine of formula (II) wherein B represents (Ci-C2o)alkylene; (Ci-C2o)alkylene substituted as defined above; or a known 3- to 20-membered heteroalkylene; and A and A' are the same, such as -NH2.
• the amine is a known aliphatic amine of formula (II) wherein B represents (CrCi5)alkylene; (CrCi5)alkylene substituted as defined above; or a known 3- to 15-membered heteroalkylene.
• the amine is a known aliphatic amine of formula (II) wherein B represents (CrCi5)alkylene; (CrCi5)alkylene substituted as defined above; or a known 3- to 15-membered heteroalkylene; and A and A are the same, such as -NH2.
• the amine is a known aliphatic amine of formula (II) wherein B represents (CrCi5)alkylene, (C2-Ci5)alkylene, (C 4 - Ci5)alkylene or (Cs-Cisjalkylene.
• the amine is a known aliphatic amine of formula (II) wherein B represents (CrCi5)alkylene, (C2-Ci5)alkylene, (C 4 - Ci5)alkylene or (Cs-Ci5)alkylene; and A and A are the same, such as -NH2.
• the amine is a known aliphatic amine of formula (II) wherein B represents a known 3- to 15-membered heteroalkylene, particularly represents a known 3- to 10-membered heteroalkylene or a known 4- to 8- membered heteroalkylene.
• the amine is a known aliphatic amine of formula (II) wherein B represents a known 3- to 15-membered heteroalkylene, particularly represents a 3- to 10-membered heteroalkylene; and A and A are the same, such as -NH2.
• the amine is a known aliphatic amine of formula (II) wherein B represents a known 3- to 15-membered heteroalkylene, particularly represents a 3- to 10-membered heteroalkylene, wherein the members are selected from carbon, S, and N atoms, as defined above.
• the amine is a known aliphatic amine of formula (II) wherein B represents a known 3- to 15-membered heteroalkylene, particularly represents a 3- to 10-membered heteroalkylene, wherein each one of the members is selected from the group consisting of: C(R X )2, CR X , -NR' X -, and -S-, wherein R x and R' x are as defined above.
• the amine is a known aliphatic amine of formula (II) wherein B represents a known 3- to 15-membered heteroalkylene, particularly represents a known 3- to 10-membered heteroalkylene, wherein the members are selected from carbon, S and N atoms as defined above; and A and A' are the same, such as -Nhh.
• the amine is a known aliphatic amine of formula (II) wherein B represents a known 3- to 15-membered heteroalkylene, particularly represents a known 3- to 10-membered heteroalkylene, wherein two of the members are S atoms and the others are carbon atoms, as defined above.
• the amine is a known aliphatic amine of formula (II) wherein B represents a known 3- to 15-membered heteroalkylene, particularly represents a known 3- to 10-membered heteroalkylene, wherein two of the members are S atoms and the others are carbon, as defined above; and A and A are the same, such as -Nhh.
• the amine is a known aliphatic amine of formula (II) wherein B represents a known 4- to 15-membered heteroalkylene, particularly represents a known 4- to 10- membered heteroalkylene, wherein the members are carbon and S atoms, as defined above.
• the amine is a known aliphatic amine of formula (II) wherein B represents a known 4- to 15-membered heteroalkylene, particularly represents a known 4- to 10-membered heteroalkylene, wherein the members are carbon and - NR'x- atoms, as defined above.
• the amine is a known aliphatic amine of formula (II) wherein B represents a known 4- to 15-membered heteroalkylene, particularly represents a known 4- to 10-membered heteroalkylene, wherein the members are carbon and S atoms, as defined above; and A and A are the same, such as -Nhh.
• the amine is a known aliphatic amine of formula (II) wherein B represents a known 4- to 15- membered heteroalkylene, particularly represents a known 4- to 10-membered heteroalkylene, wherein the members are carbon and -NR' X - atoms, as defined above; and A and A are the same, such as -Nhh.
• the amine is a known aliphatic amine of formula (II) wherein B represents a known 4- to 15-membered heteroalkylene, particularly represents a known 4- to 10-membered heteroalkylene, wherein two of the members are S atoms and the remaining members are carbon atoms, as defined above.
• the amine is a known aliphatic amine of formula (II) wherein B represents a known 4- to 15-membered heteroalkylene, particularly represents a known 4- to 10-membered heteroalkylene, wherein one of the members is -NR'x- and the remaining members are carbon atoms, as defined above.
• the amine is a known aliphatic amine of formula (II) wherein B represents a known 4- to 15-membered heteroalkylene, particularly represents a known 4- to 10-membered heteroalkylene, wherein two of the members are S atoms and the remaining members are carbon atoms, as defined above; and A and A are the same, such as -Nhh.
• the heteroalkylene is one including two S atoms
• the heteroalkylene can also be referred as "alkylene disulfide”.
• Illustrative non-limitative examples are cystamine, 4-aminophenyl disulfide and bis-amino polyethyleneglycol disulfide, among others.
• the amine is a known aliphatic amine of formula (II) wherein B represents a known 4- to 15-membered heteroalkylene, particularly represents a known 4- to 10-membered heteroalkylene, wherein one of the members is -NR' X - and the remaining members are carbon atoms, as defined above; and A and A' are the same, such as -Nhh.
• the amine is a known aliphatic amine of formula (II), wherein B represents a known 4- to 15-membered heteroalkylene, particularly represents a known 4- to 10-membered heteroalkylene, wherein each one of the members is selected from the group consisting of C(R X )2, CR X , -NR' X -, and -S-, wherein R x and R' x are as defined above.
• the amine is a known aliphatic amine of formula (II) wherein B represents a known 3- to 15-membered heteroalkylene, particularly represents a known 3- to 10-membered heteroalkylene, wherein:
• one or two of the members are -S- atoms and the others are carbon atoms selected from C(R X )2, and CR X ; or, alternatively,
• one or two of the members are -NR' X -, and the others are carbon atoms selected from the group consisting of C(R x ) 2 , and CR x; wherein Rx is as defined above;
• one of the members is -S- atoms and the others are carbon atoms selected from the group consisting of C(R x ) 2 , and CR X ; or, alternatively,
• one of the members is -NR' X -, and the others are carbon atoms selected from the group consisting of C(R x ) 2 , and CR x; ;
• two of the members are -S- atoms and the others are carbon atoms selected from the group consisting of C(R x ) 2 , and CR X ; or, alternatively,
• two of the members are NR' X -, and the others are carbon atoms selected from the group consisting of C(R x ) 2 , and CR x; ; wherein R x and R' x are as defined above.
• the known aliphatic amine of formula (II) is selected from the group consisting of an amine of formula (111), an amino of formula (M2), and an amine of formula (M3): (111) (II2) (113) wherein a is an integer from 1 to 20; b, d, and e are independently an integer from 1 to 10, more particularly b, d, and e are the same; and f, and g are independently an integer from 1 to 10, more particularly f and g are the same.
• the known aliphatic amine of formula (II) is selected from the group consisting of hexamethylenediamine, octamethylenediamine, dodecamethylenediamine, cystamine, tris-(3-aminopropyl)amine, and tris-(2- aminopropyl)amine, more particularly selected from hexamethylenediamine, dodecamethylenediamine, octamethylenediamine and cystamine.
• the amine is an aromatic amine of formula (llbis). In another embodiment of the first aspect of the invention, optionally in combination with any of the embodiments provided above or below, the amine is an aromatic amine of formula (llbisl):
• the amine is an aromatic amine of formula (llbis) or (llbisl) which comprises at least two amino groups.
• the amine is an aromatic amine of formula (llbis) or (llbisl), and W represents -NR t R't.
• the amine is an aromatic amine of formula (llbis) or (llbisl), W represents -NR t R' t , and R m , R'm, Rtand R' t are the same.
• the amine is an aromatic amine of formula (I I bis) or (llbisl), W represents -NR t R’t, and R m , R' m , Rtand R' t are the same and represent -H.
• the amine is an aromatic amine of formula (I Ibis) or (llbisl), W represents -NR t R’ t , R m and R' m are the same and represent -H, and R t and R' t are the same and are as defined above.
• the amine is an aromatic amine of formula (I Ibis) or (llbisl), W represents -NRtR’t, and R t and R' t are the same and are other than hydrogen.
• the amine is an aromatic amine of formula (I Ibis) or (llbisl), W represents -NR t R'tgrass and R m and R' m are hydrogen; and R t and R' t are the same and are other than hydrogen.
• the amine is an aromatic amine of formula (I Ibis) or (llbisl)
• W represents -NR t R’ t
• R m and R' m are the same and represent -H
• R t and R' t represent an aromatic ring as defined above under the first aspect of the invention.
• the amine is an aromatic amine of formula (I Ibis) or (llbisl)
• W represents -NR t R’ t
• R m and R' m are the same and represent -H
• each one of R t and R' t represent an aromatic ring having 6 members as defined above under the first aspect of the invention.
• the amine is an aromatic amine of formula (I Ibis) or (llbisl), W represents -NR t R’ t , and each one of R t and R' t represent an aromatic ring as defined above.
• the amine is an aromatic amine of formula (I Ibis) or (llbisl), W represents -NR t R’ t , and each one of R t and R' t represent an aromatic ring having 6 members as defined above.
• the amine is an aromatic amine of formula (I Ibis) or (llbisl), W represents -NR t R’ t , and each one of R t and R' t represent an aromatic ring having 6 members, all the members being -CR Z -, wherein R z is as defined above.
• the amine is an aromatic amine of formula (I Ibis) or (llbisl), W represents -NR t R't, wherein R t and R' t are the same and represent an aromatic ring having 6 members, all the members, being -CR Z - members, wherein R z is as defined above.
• the amine is an aromatic amine of formula (I Ibis) or (llbisl)
• W represents -NR t R' t
• R m and R' m are the same and represent -H
• each one of R t and R' t represent an aromatic ring having 6 members, all the members being -CR Z -, wherein R z is as defined above.
• the amine is an aromatic amine of formula (I Ibis) or (llbisl), W represents -NR t R' t , R m and R' m are the same and represent -H, R t and R' t are the same and represent an aromatic ring having 6 members, all the members, being -CR Z - members, wherein R z is as defined above.
• the amine is an aromatic amine of formula (llbis) or (llbisl), and W represents *S-S-L.
• the amine is an aromatic amine of formula (llbis) or (llbisl), W represents *S-S-L, and R m and R' m are the same.
• the amine is an aromatic amine of formula (llbis) or (llbisl), W represents *S-S-L, and R m and R' m are the same and represent -H.
• the amine is an aromatic amine of formula (llbis) or (llbisl), W represents *S-S-L, R m and R' m are the same, and L represents an aromatic ring as defined above.
• the amine is an aromatic amine of formula (llbis) or (llbisl), W represents *S-S-L,
• R m and R' m are the same and represent -H, and L represents an aromatic ring as defined above.
• the amine is an aromatic amine of formula (llbis) or (llbisl), W represents *S-S-L,
• R m and R' m are the same, and L represents an aromatic ring having 6 members as defined above.
• the amine is an aromatic amine of formula (llbis) or (llbisl)
• W represents *S-S-L
• Rm and R' m are the same and represent -H
• L represents an aromatic ring having 6 members as defined above.
• the amine is an aromatic amine of formula (I Ibis) or (llbisl), W represents *S-S-L, R m and R' m are the same, and L represents an aromatic ring having 6 members, the same or different, represented by -CR V -, as defined above.
• the amine is an aromatic amine of formula (I I bis) or (llbisl), W represents *S-S-L, R m and R' m are the same and represent -H, and L represents an aromatic ring having 6 members, the same or different, particularly the same, represented by -CRv, as defined above as defined above.
• the amine is an aromatic amine of formula (llbis) or (llbisl), and L represents an aromatic ring as defined above.
• the amine is an aromatic amine of formula (llbis) or (llbisl), and L represents an aromatic ring having 6 members as defined above.
• the amine is an aromatic amine of formula (llbis) or (llbisl), and L represents an aromatic ring having 6 members, the same or different, represented by -CRv, as defined above.
• the amine is an aromatic amine of formula (llbis) or (llbisl), and L has the following formula (IV): n 1 or 2, and one of the carbon atoms forming the aromatic ring being bound to the -S- atom.
• the amine of formula (llbis) is one of formula (V), (VI) or (VII):
• the amine is selected from the group consisting of: hexamethylenediamine, octamethylenediamine, dodecamethylenediamine, cystamine, tris-(3-aminopropyl)amine, tris-(2-aminopropyl)amine, and 4,4’,4”- triaminotriphenyl amine.
• the catechol derivative and the amine solutions can be separately prepared, and then being mixed together. Or, alternatively, one of the catechol derivative and the amine can be prepared in the form of a solution and the other one be added as directly obtained from the supplier.
• the appropriate solvent system to prepare the solution(s) will depend on the polar nature of the catechol and amine, something which is part of the general knowledge of the skilled person in the art. Both, the catechol and the amine, have to dissolve in the same solvent system to carry out the crosslinking reaction.
• the catechol and amine are prepared in the form of an aqueous solution.
• aqueous solution embraces solutions consisting of only water but also combinations of water with other polar solvents such as water+alcohols or aqueous-based buffers.
• the aqueous solution is obtained by mere mixing of the compound with water. In any case, when the catechol and the amine are mixed, this step is performed under agitation (to appropriately promote the formation of the film in the air/liquid interface).
• the pH of the solution is comprised from 6.5 to 8 or from 7 to 7.5.
• the pH is of 6.5, 6.6, 6.7, 6.8, 6.9, 7, 7.1, 7.2, 7.3, 7.4,
• buffers that can be added the reaction medium to provide the intended pH value.
• Illustrative non-limitative examples are phosphate-buffered saline (PBS), carbonate- bicarbonate and citrate, among others.
• PBS phosphate-buffered saline
• the buffer can be added in any order to the reaction medium with respect to the addition of catechol derivative and the amine.
• the liquid medium comprises an aqueous-based buffer, more particularly, an aqueous-based buffer in the absence of nitrogen atoms or amino groups, even more particularly, the aqueous-based buffer being selected from the group consisting of a phosphate buffer, a carbonate buffer and a citrate buffer.
• the liquid medium is water.
• the agitation is also adjusted.
• the agitation can be performed during the whole step of cross-linking.
• the speed of agitation may not provide turbulences as they would hindrance the appropriate formation of the membrane. Whether the speed is appropriate or not can be easily confirmed by the skilled person: if no turbulence is observed in the reaction medium, this will indicate that the speed is appropriate. If, when adjusted, the skilled person observed the onset of turbulences in the liquid medium, this will be indicative that the speed is not appropriate and that it should be reduced until said turbulences disappeared.
• agitation means to be used during the whole cross- linking step are magnetic (or mechanical) means, using the lowest speed possible to avoid the turbulence in the air/liquid interface, being homogeneous during the whole procedure and avoiding erratic movement of the magnet or mechanical pieces involved in the agitation procedure.
• the skilled person can routinary determine the appropriate speed of agitation depending on the reactor's volume, liquid medium and means of agitation. For example, in case of the examples provided below, wherein the volumes were of about 20 mL, the inventors established as appropriate agitation one lower than 500 rpm using a magnetic stirrer. In one embodiment, optionally in combination with any of the embodiments provided above or below, the stirring speed is equal to or below than 450 rpm, equal to or below than 400 rpm, or equal to below than 350 rpm.
• the agitation can be performed during part of the cross-linking reaction.
• the speed of agitation can be any: once the agitation is stopped, the reaction medium is left for a period of time such as the oxidized catechol moieties that crosslink with the amino-based ligands diffuse and arrange in the interface to form the membrane.
• the agitation can stop, for example, when a visual colour change is detected due to the oxidation of the catechol moieties. Then, it is left to complete the copolymerization reaction with the amino-based ligand, finishing with the formation of a floating membrane in the air/liquid interface.
• agitation is performed during the whole step of cross-linking or alternatively during part of the cross-linking reaction.
• agitation is performed during the whole step of cross-linking such that no turbulences are provided, more particularly at a stirring speed is equal to or below than 450 rpm, equal to or below than 400 rpm, or equal to below than 350 rpm.
• agitation is performed using the lowest speed possible to avoid the turbulence in the air/liquid interface, being homogeneous during the whole procedure and avoiding erratic movement of the magnet or mechanical pieces involved in the agitation procedure, more particularly at a stirring speed is equal to or below than 450 rpm, equal to or below than 400 rpm, or equal to below than 350 rpm.
• agitation is only performed during part of the cross-linking reaction, in particular agitation is performed such that no turbulences are provided until a change in coloration is observed and then it is stopped, even more particularly agitation is performed for a period of time from 10 min to 2 hours and then it is stopped.
• the amine of formula (II) or (I I bis) is at a molar ratio excess with respect to the catechol derivative, particularly the molar ratio of the amine compound of formula (II) vs the catechol derivative is comprised from 1.1:1 to 3:1, particularly from 1.2:1 to 2:1.
• the crosslinking step is performed at a temperature comprised from 10 to 60°C. Particularly, at a temperature from 10 to 50°C, from 12 to 40°C or from 15 to 38°C.
• the crosslinking step is performed for at least a period of 24 h.ln one embodiment, optionally in combination with any of the embodiments provided above or below, step (a) is performed at a pH value from 7 to 7.5 and agitation equal to or below than 300 rpm. In another embodiment, optionally in combination with any of the embodiments provided above or below, step (a) is performed at a pH value from 7 to 7.5, agitation equal to or below than 300 rpm and the molar ratio of the amine compound of formula (II) vs the catechol derivative is comprised from 1.1:1 to 3:1, particularly from 1.2:1 to 2:1.
• the skilled person is able to adjust routine parameters such as reaction time or concentration of reagents, which helps tuning the final thickness of the membrane.
• the present invention provided a catecholamine-based membrane obtainable by the process of the invention defined above, either in the first aspect or any of the above particular embodiments.
• the chemical asymmetry shown by the membranes of the invention provides different functionalization options and a higher versatility as platforms as already explained above.
• Having different chemical groups on each side of the membrane allows for the anchoring of specific molecules depending on their activity.
• the water-contact side which is rougher, could be functionalized with growth factors, while the air- contact side (less rougher) could be functionalized with antibacterial moieties to avoid infections during the regeneration process.
• the exposed chemical groups in each side of the membrane are different, the versatility of these membranes allows for their functionalization with (bio)molecules of different chemical nature depending on the side.
• the catecholamine-based film of the invention comprises one or more molecules of interest, such as a therapeutic molecule (e.g., peptides, proteins, or antibodies, such as an antibacterial moiety (e.g., cetrimide or silver nanoparticles) or a growth factor (e.g., FGF-2 or TGF 3), among others) or a detection label (e.g., calcein, nanoparticles, such as metal nanoparticles or antibodies), among others.
• a therapeutic molecule e.g., peptides, proteins, or antibodies, such as an antibacterial moiety (e.g., cetrimide or silver nanoparticles) or a growth factor (e.g., FGF-2 or TGF 3), among others) or a detection label (e.g., calcein, nanoparticles, such as metal nanoparticles or antibodies), among others.
• a therapeutic molecule e.g., peptides, proteins, or antibodies, such as an antibacterial moiety (e.g
• the catecholamine-based membrane further comprises one or more molecules of interest selected from the group consisting of therapeutic molecules, cells, growth factors, detection labels (fluorescent active moieties, nanoparticles or antibodies), and combinations thereof.
• the invention also provides a process for preparing the catecholamine-based membranes of the invention including one or more molecules of interest, the process comprising:
• step (i.1) performing step (a) of the process as defined in the first aspect of the invention or any of the embodiments of this aspect,
• step (b) of the process of the first aspect of the invention or, alternatively, the process comprising:
• Step (i.2) is performed either directly adding to the reaction medium the molecule of interest as obtained from the supplier or in the form of an aqueous suspension (following manufacturer's instructions).
• the mild conditions used in the process of the invention advantageously allows the functionalization of the membrane in the own reaction medium wherein the membrane has been formed, which, advantageously, simplifies the process, reducing time and cost.
• the adding step can be performed by pouring the solution in the reaction medium or, in case that the membrane is covering the whole surface of the reaction medium, by injecting the molecule's solution to the reaction medium through the membrane. The latter does not negatively affect to the integrity of the membrane, which is a further indicium of the robustness and improved mechanical properties of the membranes of the invention.
• the membrane has already been isolated from the interface. Therefore, the membrane may be incorporated to a medium comprising the solution with the molecule of interest (and the side in contact with the medium is functionalized) or, alternatively, the membrane is incorporated to a medium and a solution with the molecule is injected in the solution.
• the functionalization side can be selected previously, depositing the membrane with the desired side in contact with the liquid (aqueous) phase containing the molecule of interest.
• the membranes have functional groups exposed on the surface that can be used as anchoring points. The functionalization of membrane's surface with the molecule of interest can occur by covalent bond, adsorption, or electrostatic interaction.
• the functionalization can be performed through nucleophilic or electrophilic attack depending on the chemical nature of the molecule of interest.
• acyl chloride e.g., stearoyl chloride
• amino groups e.g., hexadecamine
• thiol groups e.g., 1,8- octanedithiol
• the presence of carboxylic acids in the backbone of the molecule of interest can be used for the formation of an amide bond (peptide-like bonding) with the terminal amino groups exposed on the surface of the membranes.
• the physical adsorption of molecules could be induced due to the entrapment of the molecule of interest in the backbone of the membranes.
• the molecule of interest is covalently bound to the membrane surface of the second aspect of the invention.
• the catecholamine-based membrane of the invention further comprises one or more molecules of interest selected from the group consisting of therapeutic molecules, and detection labels (fluorescent active moieties, nanoparticles or antibodies). More particularly, the molecule of interest is covalently bound to the membrane, particularly by an amide bond.
• the covalent bond can be achieved by any routine protocol, such as by generating an amide bound between the free amino groups of the membrane of the invention and the free carboxylic groups of the molecule of interest.
• the coupling reaction in this case, can be performed using (1-ethyl-3-(3-dimethylamino) propyl carbodiimide, hydrochloride (EDC) and N-Hydroxysuccinimide (NHS).
• EDC 1-ethyl-3-(3-dimethylamino) propyl carbodiimide
• NHS N-Hydroxysuccinimide
• the formed membranes can be introduced in Petri dishes of bigger diameter with a buffer within the range pointed out above. Then, the EDC is injected in the aqueous phase.
• the active (bio)molecule e.g., antibacterial moiety, florescent dye, growth factor, etc.
• NHS agent e.g., glutathione, glutathione, glutathione, glutathione, glutathione, glutathione, glutathione, glutathione, glutathione, glutathione, glutathione, glutathione, glutathione, glutathione, glutathione, etc.
• the functionalized membranes can be extracted from the Petri dish and washed.
• the functionalization can be controlled and induced independently on both sides of the membranes, enhancing the chemical Janus behaviour of the membranes.
• catechol derivatives with different functional groups as terminal thiols, amines or acyl chloride can also be functionalized through the nucleophilic or electrophilic attack to the exposed functional groups on the membranes or the rings in the catechol-derivatives.
• the procedure would be similar as previously described.
• Some parameters such as the pH or the solvent can be routinely adjusted or selected for activating the reaction between the molecule of interest and the membrane.
• the particular Janus features of the membrane of the invention allows the efficient functionalization by both sides, which is a further distinctive trait with respect to the membranes already reported in the prior art.
• the membrane of the invention shows improved cell adhesion when compared to the membranes of the prior art. This supports its usability as adhesive. Not only that, but also, due to the particular Janus distribution, the membrane of the invention is also capable of being functionalized with different types of molecules, which supports its usability as a vehicle of a therapeutic or diagnostic molecule.
• the membrane of the invention can also be used as adhesive or to coat, due to such adhesive property, any article (such as a medical device, electronic support or sensor) requiring a catecholamine membrane.
• the membrane of the invention can be used as a part of other substrates or devices, endowing the final product with enhanced properties.
• prosthesis could be totally o partially covered with the membranes for the enhancement of biocompatibility and reducing side effects or organism rejection.
• sensors or electronical supports could be adhered to biological tissues or devices through the use of the membranes of the invention.
• the sensors or electronic supports could be as a part of the membranes in a single platform or forming a hybrid composite, where the sensor or electronical support is adhered on the desired area with the help of the membranes applied as adhesive patches.
• the catechol-based compounds (pyrocatechol(l) , caffeic acid(2), dopamine(3), 4-methylcatechol(4), pyrogallol(5), and catechin(6)) as well as the amine compounds of formula (II) (hexamethylenediamine(7), octamethylenediamine(8), dodecamethylenediamine(9), cystamine(IO), tris-(3-aminopropyl)amine(11), tris-(2- aminopropyl)amine(12) and 4,4',4”-Triaminotriphenylamine(13)), and the comparative hexylamine and polyethylenimine (PEI) were purchased from Sigma-Aldrich (Merck, Madrid, Spain) and used without further purification.
• Type 1 ultrapure water from a Milli-Q filtration system (Millipore, Burlington, MA, USA) was used in all experiments unless otherwise specified.
• different water-based buffers were used: phosphate-buffered saline (PBS, pH 7.4, Sigma-Aldrich) and aqueous carbonate buffer (pH 9.1) were prepared, dissolving 1.89 g of NaPIC03 and 265 mg of Na2CC>3 in 250 mL of Milli-Q water.
• FT-IR Fourier Transform Infrared
• Ettlingen, Germany was used in reflection mode, which is equipped with a nitrogen-cooled mercury- cadmium-telluride (MCT) detector (InfraRed Associates, Inc., Stuart, FL, USA) using a 15x reflection objective, a gold mirror as reference and scanning for 1 min with a resolution of 4 cnr 1 .
• MCT nitrogen-cooled mercury- cadmium-telluride
• XPS X-Ray Photoelectron Spectroscopy
• the samples were deposited on silicon substrates. All the data was treated with CasaXPS version 2.3.17PR1.1 (Casa Software LTD, Teignmouth, UK) and OriginPro version 8.0988 (OriginLab Corporation, Northampton, MA, USA) software.
• SEM Scanning Electron Microscopy
• SEM scanning electron microscopy
• the samples were prepared by deposition of the free-standing membranes on aluminium stubs.
• the samples were metalized by depositing on the surface a thin platinum coating (5 nm) using a sputter coater (Leica EM ACE600). Aluminium-tapped supports (pin stubs) were provided.
• Atomic Force Microscopy SFM
• Surface topography imaging of the different samples was carried out in ambient air in tapping mode using beam shaped silicon cantilevers (Nanosensors, nominal force constant: 5 N ⁇ ht 1 , tip radius: ⁇ 7 nm) on an Agilent 5500 AFM/SPM microscope (Keysight Technologies, Santa Clara, CA, USA) combined with PicoScan5 version 1.20 (Keysight Technologies) software.
• An external X-Y positioning system (closed-loop, 12 NPXY100E from nPoint, USA) was used.
• Image processing was done using open source software: WSxM version 3.1 (Nanotec Electronica, Madrid, Spain) and Gwyddion version 2.46 (CMI, Brno, Czech Republic).
• CA Contact Angle
• OM Optical and Fluorescence Microscopy
• UV-vis spectroscopy Ultraviolet-visible spectroscopy (UV-vis) was performed using a Cary 4000 UV-vis spectrometer (Agilent Technologies, Santa Clara, CA, USA) within range wavelengths from 200 to 800 nm and a 1 cm path length quartz cuvette (QS 10 mm). The baseline was corrected using a blank sample of pure solvent. All the measurements were taken under atmospheric conditions.
• UV-vis Ultraviolet-visible spectroscopy
• the PBS was removed, allowing for the membrane to cover the bottom of the well.
• the membranes were seeded with the cells (25000 cells/membrane) added in 50 pi of the medium. Subsequently, the membranes were incubated for 30 min and after this time, the wells were filled with 350 mI of medium. The membranes with the cells were incubated for different times: 1 day, 3 days, 7 days, 14 days and 30 days.
• the membranes were washed for at least five times with PBS to eliminate the non- adhered cells. Different criteria were stablished in order to evaluate the adhesion, proliferation and cell differentiation for each cell type and membranes.
• the membranes were washed in PBS for at least five times in order to remove unattached cells.
• the cells on the surface were counted using an image analysis software (ImageJ), counting the cells attached in the two different sides and at different time points, determining the density of cells.
• the proliferation was evaluated by analysing with optical and/or electronic microscopy the formation of cell networks and their preferential growth in specific directions as occurred in common in vitro cell culture.
• the cell differentiation was evaluated for the ASC cells, identifying the formation of different cell types through the observation of different morphology and cell structure using optical and/or electronic microscopy.
• the medium was enriched with growth factors (TGF 3 and BMP 6).
• TGF 3 and BMP 6 growth factors
• the cells were treated with formaldehyde for 1 h and subsequently washed three times with PBS. The membranes with cells were stored in the fridge with PBS.
• the cells were previously stained with a Live/Dead kit test (Thermo Fisher Scientific) following the specifications indicated by the manufacturer.
• the corresponding catechol- and amine- derivative were placed in solid in the reaction vessel, the latter being in a molar ratio excess of the amine (1 : 1.5). Then, the addition of PBS was performed and the pH of the solution was adjusted to 7.4. The reaction vessel was covered with Parafilm® with a hole of 2 mm in diameter, allowing for the entrance of oxygen. The formation of the free-standing floating membranes was performed under magnetic stirring at 300 rpm, and at room temperature. The polymerization reaction took place in the liquid-air interphase through the oxidation of the catechol-derivatives and its reaction with the amine-based ligands, without the need of physical substrate or the formation of in situ substrates with other secondary molecules.
• the (bio)molecules were anchored through a coupling reaction using (1-ethyl-3-(3-dimethylamino) propyl carbodiimide, hydrochloride (EDO) and N-Hydroxysuccinimide (NHS).
• This coupling reaction allows for the formation of amide bonds between the amino groups exposed in the membranes and the carboxylic groups of the (bio)molecules functionalized.
• the formed membranes were introduced in Petri dishes of bigger diameter compared with the membranes and containing PBS and under magnetic stirring (500 rpm). Then, an aqueous solution of EDO (5mM) was injected in the aqueous phase.
• the active (bio)molecule together with the NHS agent were injected in the aqueous phase.
• the antibacterial moiety (vanillic acid) or the fluorescent dye (calcein) were dissolved in water (10 mM) and subsequently mixed with NHS (10 mM).)
• the reaction was stirred slowly for 60 min.
• the functionalized membranes were isolated from the Petri dish, washed for at least 5 times with a flux of distillated water and dried under vacuum.
• This approach allowed for different functionalization with high yield (approx. 55-60%, depending on the functionalized molecule), thanks to the membranes composition, which are rich in amino groups exposed on the surface.
• the functionalization can be controlled and induced independently on both sides of the membranes, enhancing the chemical Janus behaviour of the membranes.
• the membranes were paced first
• the membranes of the invention were easily isolated by using common tweezers and properly handled and translated to other containers for their storage.
• the resulting membranes presented high flexibility without breaking when one end of the membranes was bent 180° putting into contact with the other end of the membrane. This was performed in both humid and dried membranes without observation of any crack or fissure by SEM. This bending movement was performed manually for at least 50 cycles corroborating the flexibility of the membranes. Additionally, torsion movements were performed to check the flexibility limits of the membrane, showing excellent robustness.
• the membrane was a catecholamine-based membrane through several measures using FT-IR and XPS. Depending on the chemical nature of the catechol derivative and the amine-based ligand, different frequency ranges of FT-IR spectra were evaluated. Firstly, the presence of catechol (3500- 3000 cm ⁇ 1 ) and amine (1700-1500 cnr 1 ) groups was the first indication of the formation of the crosslinking polymer. Subsequently, depending on the type of catechol or amine-based molecules, specific bands were identified within certain ranges.
• bands corresponding to an amide bond appeared in the range of 1650-1500 cnr 1 and between 1290-1200 cm- 1 ⁇ specifically in 1-7 (1500 and 1260 cnr 1 ), 1-8 (1499 and 1268 cm- 1 ), 1-9 (1519 and 1261 cm- 1 ), 1-10 (1508 and 1260 cm- 1 ), 1-11 (1547 and 1281 cm- 1 ), 1-12 (1511 and 1263 c r 1 ), 2-7 (1546 and 1270 c r 1 ), 2-8 (1515 and 1260 c r 1 ), 2-9 (1635 and 1210 cnr 1 ), 2-10 (1595 and 1261 cnr 1 ), 2-11 (1529 cnr 1 ), 2-12 (1538 and 1204 cnr 1 ), 3-7 (1511 and 1231 cnr 1 ), 3-8 (1231 cnr 1 ), 3-9 (1252 cnr 1 ), 3-10 (1564 and 1251 cm- 1 ), 3-11 (1209 cm- 1 ), 3-12
• the free-standing membranes of the invention exhibited Janus character in terms of morphology.
• both sides of the films were found to be different.
• the surface in contact with the water had embedded nanoparticles of the same cathecol-amine material. These nanoparticles were formed as a side product and were found as precipitate and embedded in the water-contact side.
• the precipitated NPs were centrifuged and isolated for their characterization by FT-IR, corroborating its catechol amine composition. Besides, the formation of the membranes was followed through the time, taking aliquots form the interface at different time points and observed by SEM. The SEM images showed the process through the NPs were embedded.
• PEI-based membrane showed a chemical Janus character as PEI was perfectly separated within the formed structure forming two different domains and different porosity depending on the side. However, no nanopatterning was detected. Due to the plastic-like morphology (rigidity and smooth sides) exhibited by PEI membranes the roughness of the PEI-based membrane was very low in both sides when analyzed SEM images, presenting similar characteristics. This low roughness and lack of nanopatterning difficult the adhesion of cells on the membrane, as discussed in the following sections.
• this comparative membrane did not show any Janus character as both sides of the membrane were very similar, as the use of a substrate avoid the formation of a floating membrane in the interphase (membranes of the invention) and the ordering of the molecules due to their polarity on the water and air phase cannot take place.
• AFM topographic profiles were evaluated to verify the thickness measurements obtained by SEM.
• SEM images showed different roughness depending on the contact side of the membranes. Specifically, water-contact side presented an unexpected higher roughness. For this reason, AFM was performed on the water-contact side.
• the membranes of the invention exhibited nanoparticles embedded, offering the highest roughness to the surface.
• Several areas were explored with regular profiles from different zones with a height of around 275 nm.
• the nanoparticles embedded in the membrane correlated with SEM observations. In the case of the air-contact side, a smoother surface was found, with roughness less than 10 nm.
• the profile height match within the interval of thickness estimated by SEM, being in the range of 200-600 nm, depending on the membrane.
• the membranes were characterized using optical microscopy. This was performed due to the observed interaction of light with the surface of the membranes, which was expressed in the reflection of different colors depending on the thickness of the surface. This phenomenon confirmed both the different thicknesses of the membranes and the nanopatterning on the surfaces. The above was confirmed by determining the FT-IR, XPS and contact angle for each case. This characterization was performed for all the membranes of the invention and the comparatives. In all the cases similar results were obtained.
• the spectra were analyzed and shared the following characteristics.
• the broad band in the range of 3500- 3000 cm ⁇ 1 , corresponding to the stretching vibrations of hydroxyl (—OH) and in the range of 1700-1500 cnr 1 for amine (-NFI2) groups, whose peaks could be appreciated in the catechol derivatives and amine-based compound spectra, respectively.
• the peaks in the range of 3000-2500 cnr 1 are associated with asymmetric and symmetric stretching vibrations of aliphatic carbons (C— H).
• the peak at 1700 crrNcorresponded to the presence of quinones (C 0).
• the peaks in the range of 1200-1450 cnr 1 belongs to a secondary amine binding an alkyl or an aromatic ring.
• the chemical composition of the membranes matches the functional groups of the reagents.
• the FT-IR spectra showed similar results with the presence of specific bands for the amino and catechol groups. Additionally, for each specific catechol-derivative, other representative signals depending on the functional groups of the molecules can be assigned. These results also confirmed the successful copolymerization between the catechol- and amino-based molecules following the established methodology.
• the wettability of the membranes was tested using contact angle equipment. Previous to performing the measurements, the membranes were placed in an oven at 170°C for 2 h to completely dry them and stored under vacuum to remove all the water molecules. This drying process was followed by weighting the membranes until the lowest weight was reached, thus indicating the loss of all the water.
• the hydrophobic/hydrophilic character of the membranes was determined. As observed in other characterization techniques, the wettability was different depending on the side where it was measured. The water-contact side has a more hydrophilic behaviour with contact angles around 25°, while the air-contact side has higher angles around 40°, denoting higher hydrophobicity. Nevertheless, overall the membranes show an intermediated hydrophilic/hydrophobic behaviour. This surface property could be changed by anchoring hydrophobic or hydrophilic moieties by using the exposed functional groups present on the membranes. Playing with the wettability, the adhesion of the membranes can be adjusted depending on the final tissue to be applied.
• the inventors functionalized the membranes with vanillic acid, which has a well-known antibacterial activity, through the EDC/NHS coupling reaction, following the procedure described above.
• the tests were performed as a proof-of-concept in six different membranes (1-7, 1-8, 2-7, 2-8, 3-9, 3-10)
• the membranes were characterized by different means. FT-IR spectra confirmed the appearance of a band at 1665 cnr 1 assigned to the amide bond formation through the free amino groups and the carboxylic acid of the vanillic acid. Furthermore, specific peaks from the vanillic acid were incorporated in the spectra corresponding to the functionalized membranes.
• the membranes (1-7, 1-8, 2-7, 2-8, 3-9, 3-10) were functionalized with a fluorescent dye (calcein).
• the anchoring of the dye to the membrane was achieved via EDC/NHS coupling reaction, following the procedure described above.
• the membranes were characterized using a fluorescent microscope.
• the as-functionalized membranes of the invention presented very high fluorescence with a time exposition of around 450 ms, which was enough for the acquisition of the images without saturation of the signal. Additionally, as in the case of antibacterial moieties, FT-IR spectra measurements corroborated the functionalization of the membrane with the fluorescent dye, appearing the typical bands corresponding to the calcein reagent (1750, 1630, 1445 and 1280 cm ⁇ 1 ). Besides, contact angle measurements showed an increase of water contact angle of around 30° after functionalization of the membranes, thus indicating a successful modification of the surface.
• the PEI-based membrane of the prior art degraded remarkably faster when compared with the membranes of the invention, detecting traces of PEI after 2 weeks in a dialysis experiment.
• This delivery of the PEI affected the robustness of the membrane.
• PEI reported toxicity in biological environments, being highly cytotoxic in different cell lines. This toxicity hampered the application of PEI-based membranes for tissue regeneration and other bioapplications.
• the PEI-based membrane was tested. The results showed higher cytotoxicity compared with the membranes of the invention. After 24 h, all the membranes of the invention showed cell viability higher than 90% in all the cell lines tested. However, PEI-based membranes showed an increased toxicity with cell viability around 65%. This higher toxicity has been associated with the fast degradation of PEI-based membrane, inducing the release of PEI which has a well-known cytotoxic effect. This is one of the main reasons why the PEI-based membranes cannot be used in biological applications.
• the different cell lines were seeded on the membranes placed on the bottom of the cell culture plates and incubated with cell culture medium at different time points until 21 days. At the different time points, the membranes were extracted and washed for their characterization.
• the cells were perfectly adhered to the membrane surface (both sides) with a preferential growth in the side in contact with water which was the one with the nanopatterning. This preferential growth was observed with a higher cell density on the water-contact side compared with the air-contact side (an increase of the 45%).
• Different images were taken with optical and electronic microscopy.
• the cells adhered on the membranes through the same mechanisms observed in common cell culture plate, showing their natural cell morphology and proliferation in preferred orientations.
• the cells were marked with fluorescent moieties to observe them using fluorescent microscopy and also cells were fixed for their observation in SEM.
• the membranes were washed to remove non-attached cells.
• PEI-based membranes showed very poor cell adhesion with very low density of cells.
• the cell density on PEI-based membranes decreased around 70%. This could be associated, together with the toxic nature of PEI, to the surface characteristics of the membranes made with this polyimine, that hamper the interactions between the material and the cells.
• the adhesion of the membranes was also tested in ex vivo tissues (cartilage and skin from pig).
• the tissues were obtained directly from euthanized animals for other purposes used by the Veterinary Faculty of the Autonomous University of Barcelona.
• the objective was to corroborate the adhesion of the membranes in different types of biological tissues and in humid conditions.
• different membranes of the invention (1- 7, 1-8, 1-9, 1-10, 1-11, 1-12, 2-7, 2-8, 2-9, 2-10, 2-7, 2-8, 2-9, 2-10, 2-11, 2-12, 3-7, 3-8, 3-9, 3-10, 4-7, 4-8), were cut to different sizes and attached to the tissues.
• the tests were performed with non- and functionalized membranes and membranes with and without cells.
• the area could be cleaned without affecting the adhered membrane, which remained in the area without moving.
• the biological tissues with the adhered membranes were immersed in water for months, observing that the membrane remained adhered to the tissue without detaching form the tissue.
• the in vivo assays were performed with Dawley Sprague rats of female and male sex. Seven membranes of different composition were tested (1-7, 1-12, 2-7, 3-7, 3-11, 5-1 and 5-11) with and without ASC cells (see above).
• the membranes were placed in cartilage, bone and muscle, showing excellent adhesion to the tissue with no signal of rejection. Besides, no inflammation, erythema and edema were observed. These preliminary results demonstrated the excellent in vivo tolerability and biocompatibility.
• the membrane based on PEI was tested, showing very low adhesion to biological tissues due to its very low roughness and lack of interactions between the membrane and the tissue. Besides, its lack of flexibility made it difficult to apply it correctly, resulting in the membrane not being able to cover the biological tissue adequately. Due to its low adhesion to the tissue and rigidity, it was impossible to continue with the test and it had to be withdrawn.
• a process for preparing a catecholamine-based membrane comprising the steps of: a) cross-linking a catechol derivative with an amine selected from the group consisting of: a.1) a known aliphatic amine hydrocarbon of formula (II)
• a and A' are the same or different and represent -NRiR'i
• B represents a (Ci-C2o)alkylene; (Ci-C2o)alkylene substituted with one or more substituents selected from the group consisting of: -OH, halogen, -NO2, cyano, -0-(Ci-Cio)alkyi, -C(0)0R2, and -NR 3 R’ 3 ; (C2-C2o)alkenylene; (C2-C2o)alkenylene substituted with one or more substituents selected from the group consisting of: -OH, halogen, -NO2, cyano, -0-(Ci-Cio)alkyi, -C(0)0R4, and -NRsR's; (C2-C2o)alkynylene; (C2-C2o)alkynylene substituted with one or more substituents selected from the group consisting of: -OH, halogen, -NO2,
• A is bound to the first atom member forming part of the B biradical hydrocarbon backbone
• A is bound to the last atom member forming part of the B biradical hydrocarbon backbone; wherein the "first” and “last” atom members are identified reading the B biradical hydrocarbon backbone from left to right or vice versa;
• R 2 , R 4 , R6, Re, R 10 and R 12 are independently selected from the group consisting of - H;
• Cio)alkyl (Ci-Cio)haloalkyl; (C2-Cio)alkenyl; (C2-Cio)al kynyl; and (Ci-Cio)alkyl substituted with one or more substituents selected from the group consisting of -OH, -NO2, cyano, -0-(Cr Cio)alkyl, -C(0)0Ru and -NRisR’is;
• Ri3, R’ 13, Ru, Ri5 and R'is are the same or different and are selected from the group consisting of: -H; (Ci-Cio)alkyl; (Ci-Cio)haloalkyl; (C2-Cio)alkenyl; and (C2-Cio)alkynyl;
• a "known 3- to 20-membered heteroalky lene” means a known saturated chain consisting of from 3 to 20 members selected from the group consisting of C(R X )2, CR X , -N-, -NR' X -, -S-, and -0-, provided that: (a) at least one of the members is -N-, -NR' X -, -S-, or -0-; and (b) the first and the last members forming the backbone of the heteroalkylene are carbon atoms;
• a "known 3 to 20-membered heteroalkenylene” means a known unsaturated chain consist
• Rxi, R x 2, R16, Ri7, R'i7, and R' x are independently selected from the group consisting of -H, (Ci-Cio)alkyl, (C2-Cio)alkenyl, (C2-Cio)al kynyl, and (Ci-Cio)haloalkyl; and a.2) an aromatic amine of formula (llbis):
• L is selected from the group consisting of: (Ci-Cio)alkyl substituted with one or more substituents selected from the group consisting of -OH, -NO2, cyano, -0-(Ci-Cio)alkyi, -C(0)0R 28 , and -NR28R’2s, provided that at least one of the substituents is -NR2sR'28; (Ci-Cio)haloalkyl substituted with one or more substituents selected from the group consisting of -OH, -NO2, cyano, -0-(Ci-Cio)alkyi, -C(0)0R 28 , and -NR2sR'28, provided that at least one of the substituents is -NR28R'2s; (C2-Cio)alkenyl substituted with one or more substituents selected from the group consisting of -OH, -NO2, cyano, -0-(Ci-Cio)alkyi, -
• R m , R' m , R t and R' t are the same or different and are selected from the group consisting of: H, (Ci-Cio)alkyl; (Ci-Cio)haloalkyl; (C2-C 10) al keny I ; (C2-C 10) al ky ny I ; (Ci-Cio)alkyl substituted with one or more substituents selected from the group consisting of -OH, -NO2, cyano, -0-(C 1 -C 10) al ky I , -C(0)0R 29 , and -NR 3 OR'3O; and a known aromatic ring having 5 or 6 members selected from the group consisting of -CR z -, -N-, -NR' z, -0-, and -S-; at least one of R v , is -NR 3 IR’ 3 I and the other(s) R v are selected from the group consisting of H, -
• Cio)alkyl -C(0)0R 32 , and -NR 33 R' 33 ;
• R z , and R’ z are independently selected from the group consisting of: H, (Ci-Cio)alkyl; (Ci-Cio)haloalkyl;
• B represents a known 3- to 15-membered heteroalkylene, particularly represents a 3- to 10-membered heteroalkylene, wherein each one of the members is selected from the group consisting of: C(R X )2, CR X , -NR' X -, and -S-, wherein R x and R' x are as defined in clause 1.
• B represents a known 4- to 15-membered heteroalkylene, particularly represents a known 4- to 10-membered heteroalkylene, wherein each one of the members is selected from the group consisting of C(R X )3 ⁇ 4 CR X , -NR' X -, and -S-, wherein R x and R' x are as defined in clause 1.
• one of the members is -NR' X -, and the others are carbon atoms selected from the group consisting of C(R x ) 2 , and CR x; ; (e) two of the members are -S- atoms and the others are carbon atoms selected from the group consisting of
• a is an integer from 1 to 20; b, d, and e are independently an integer from 1 to 10, more particularly b, d, and e are the same; and f, and g are independently an integer from 1 to 10, more particularly f and g are the same; more particularly is selected from the group consisting of: hexamethylenediamine, octamethylenediamine, dodecamethylenediamine, cystamine, tris-(3-aminopropyl)amine, and tris-(2- aminopropyl)amine.
• R m , R' m , and W are as defined in clause 1.
• Clause 18 The process according to any of the clauses 1, 16-17, wherein the amine is an aromatic amine of formula (llbis) or (llbisl), and W represents -NR t R't.
• Clause 19 The process according to any of the clauses 1, 16-18, wherein the amine is an aromatic amine of formula (llbis) or (llbisl), W represents -NR t R't, and R m , R' m , Rtand R' t are the same.
• each one of R t and R' t represent an aromatic ring as defined in clause 1.
• each one of R t and R' t represent an aromatic ring having 6 members as defined in clause 1.
• Clause 29 The process according to any of the preceding clauses, wherein the amine is an aromatic amine of formula (llbis) or (llbisl), and W represents *S-S-L.
• Clause 30 The process according to any of the preceding clauses, wherein the amine is an aromatic amine of formula (llbis) or (llbisl), W represents *S-S-L, and R m and R' m are the same.
• Clause 31 The process according to any of the preceding clauses, wherein the amine is an aromatic amine of formula (llbis) or (llbisl), W represents *S-S-L, and R m and R' m represent -H.
• Clause 32 The process according to any of the preceding clauses, wherein the amine is an aromatic amine of formula (llbis) or (llbisl), L represents an aromatic ring as defined in clause 1.
• Clause 37 The process according to any of the preceding clauses, wherein the amine is selected from the group consisting of: hexamethylenediamine, octamethylenediamine, dodecamethylenediamine, cystamine, tris-(3-aminopropyl)amine, tris-(2-aminopropyl)amine, and 4,4',4”-triaminotriphenylamine.
• Ri 8 , Ri 9 , R'i 8 and R’1 9 are the same or different and are selected from the group consisting of:
• R' y is selected from the group consisting of -H, (Ci-Cio)al kyl, (C 2 -Cio)alkenyl, (C 2 -Cio)alkynyl, and (Ci-Cio)haloalkyl;
• R20, R'20, R21, R’21, R23, R'23, R25, and R'25 are the same or different and are selected from the group consisting of: -H; (Ci-Cio)alkyl; (Ci-Cio)haloalkyl; (C 2 -C 10 ) al keny I ; (C 2 -C 10 ) al ky ny I ; (Ci-Cio)alkyl substituted with one or more substituents selected from the group consisting of: -OH, halogen, nitro, cyano, (Ci-Cio)alkyl, (Cr Cio)haloalkyl, -NR26R’26, -C(0)0R2z, and -0-(C 1 -C 10) al ky I ; R 22 and R 24 are independently selected from the group consisting of: H, (Ci-Cio)alkyl, (Ci-Cio)haloalkyl, (C
• Cio alkenyl
• R 26 , R' 26 and R 27 are the same or different and are selected from the group consisting of: -H; (Ci-Cio)alkyl; (Ci-Cio)haloalkyl; (C 2 -C 10 ) al keny I ; and (C 2 -C 10 ) al ky ny I ; .
• Clause 39 The process of any one of the preceding clauses, wherein the catechol derivative is one of formula (III) wherein:
• - Ri 8 and f are the same or different and are selected from the group consisting of: -H; -OH; (Ci-Cio)alkyl; (CrCio)alkyl substituted as defined in clause 38; and (C2-Cio)alkenyl substituted as defined in clause 38; or, alternatively,
• Ri 8 and R1 9 is a known ring system consisting of two rings, each one of the rings (a) consisting of 5-6 members selected from the group consisting of -C(R y )2 -, -CR y -, -N-, -NR' y -, -S-, and -0-, (b) being saturated, partially unsaturated or aromatic, and (c) being isolated, partially isolated or fused; wherein R y and R' y are as defined in clause 38; or, alternatively, - one of Rie and R1 9 is a known ring system consisting of two rings, each one of the rings (a) consisting of 6 members selected from the group consisting of -C(R y ) 2 -, -CR y -, -N-, -NR’y, -S-, and -0-, (b) being saturated, partially unsaturated or aromatic, and (c) being fused; wherein R y and R' y are as
• - one of Rie and Rig is a known ring system consisting of two rings, each one of the rings (a) consisting of 6 members selected from the group consisting of -C(R y ) 2 -, -CR y -, -N-, -NR’y, -S-, and -0-, provided that at least one of the rings includes a heteroatom (-N-, -NR' y , -S-, and -0-); (b) being saturated, partially unsaturated or aromatic, and (c) being fused; wherein R y and R' y are as defined in clause 38; or, alternatively,
• - one of Rie and Rig is a known ring system consisting of two rings, each one of the rings (a) consisting of 6 members selected from the group consisting of -C(R y ) 2 -, -CRy, -N-, -NR'y, -S-, and -0-, provided that at least one of the rings includes a -0- heteroatom; (b) being saturated, partially unsaturated or aromatic, and (c) being fused; wherein R y and R' y are as defined in clause 38; or, alternatively,
• - one of Rie and R1 9 is a known ring system consisting of two rings, each one of the rings (a) consisting of 6 members selected from the group consisting of -C(R y ) 2 -, -CRy, -0-, provided that at least one of the rings includes a -O-heteroatom; (b) being saturated, partially unsaturated or aromatic, and (c) being fused; wherein R y and R' y are as defined in clause 38; or, alternatively,
• - one of Rie and R1 9 is a known ring system consisting of two rings, each one of the rings (a) consisting of 6 members selected from the group consisting of -C(R y ) 2 -, -CRy, -0-, provided that only one of the rings includes a -O-heteroatom; (b) being saturated, partially unsaturated or aromatic, and (c) being fused; wherein R y and R' y are as defined in clause 38.
• Clause 40 The process according to any of the preceding clauses, wherein the catechol derivative is one of formula (III) wherein one of the Rie or R1 9 is -H and the other is as defined in any of the above clauses, in particular in clauses 38-39.
• Clause 43 The process according to any one of the previous clauses, wherein the pH is comprised from 6.5 to 8 or from 7 to 7.5; or, the pH is selected from the group consisting of 6.5, 6.6, 6.7, 6.8, 6.9, 7, 7.1, 7.2, 7.3,
• Clause 46 The process according to any one of the previous clauses, wherein the crosslinking step is performed at a temperature comprised from 10 to 60°C.
• Clause 47 The process according to any one of the previous clauses, wherein the crosslinking step is performed for at least a period of 24 h.
• Clause 48 The process according to any one of the previous clauses, wherein the liquid medium comprises an aqueous-based buffer, more particularly, an aqueous-based buffer in the absence of nitrogen atoms or amino groups, even more particularly, the aqueous-based buffer being selected from the group consisting of a phosphate buffer, a carbonate buffer and a citrate buffer.
• Clause 49 The process according to any one of the previous clauses, wherein the liquid medium is water.
• the catecholamine-based membrane according to the preceding clause which further comprises one or more molecules of interest selected from the group consisting of therapeutic molecules, cells, growth factors, detection labels (fluorescent active moieties, nanoparticles or antibodies), and combinations thereof.
• Clause 52 The catecholamine-based membrane according to clause 51, wherein the molecule of interest is covalently bound to the membrane, particularly by an amide bond.
• Clause 53 A process for preparing the catecholamine-based membranes as defined in the preceding two clauses, the process comprising: (i.1) performing step (a) of the process as defined in clause 1,
• step (1.3) performing step (b) of the process as defined in clause 1; or, alternatively, the process comprising:
• Clause 55 Use of the catecholamine-based membrane according to clause 50 as a vehicle of a molecule of interest such as a therapeutic or label molecule.
• Clause 56 A catecholamine-based membrane as defined in any of the clauses 51 to 52, wherein the molecules of interest are therapeutic molecules for use in therapy, or alternatively a self-standing catecholamine-based membrane as defined in any of the clauses 47 to 48, wherein the molecules of interest are detection labels for use or diagnosis.
• Clause 57 A catecholamine-based membrane as defined in any of the clauses 51 to 52, wherein the molecules of interest are cells, growth factors or combinations thereof for use in regenerating tissues.
• Clause 58 An article partially or completely coated with the membrane as defined in any one of the clauses 50 to 52.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Life Sciences & Earth Sciences (AREA)
• Polymers & Plastics (AREA)
• Organic Chemistry (AREA)
• Animal Behavior & Ethology (AREA)
• Epidemiology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Oral & Maxillofacial Surgery (AREA)
• Transplantation (AREA)
• Dermatology (AREA)
• Surgery (AREA)
• Engineering & Computer Science (AREA)
• Materials Engineering (AREA)
• General Chemical & Material Sciences (AREA)
• Molecular Biology (AREA)
• Biomedical Technology (AREA)
• Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Materials For Medical Uses (AREA)
• Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)

Priority Applications (7)

Applications Claiming Priority (2)

Publications (1)

Family

ID=76553693

Family Applications (1)

Country Status (8)

Families Citing this family (1)

Citations (3)

Family Cites Families (1)

• 2022
  • 2022-06-09 IL IL309198A patent/IL309198A/en unknown
  • 2022-06-09 WO PCT/EP2022/065757 patent/WO2022258780A1/en not_active Ceased
  • 2022-06-09 JP JP2023576175A patent/JP2024526426A/ja active Pending
  • 2022-06-09 AU AU2022288381A patent/AU2022288381A1/en active Pending
  • 2022-06-09 KR KR1020247000896A patent/KR20240040725A/ko active Pending
  • 2022-06-09 EP EP22733055.2A patent/EP4352123A1/en active Pending
  • 2022-06-09 US US18/568,815 patent/US20240277896A1/en active Pending
  • 2022-06-09 CA CA3221278A patent/CA3221278A1/en active Pending

Patent Citations (3)

Non-Patent Citations (6)

Also Published As

Similar Documents

Legal Events